Currently, the only treatment available for acute or chronic end-stage liver disease is liver transplantation. There is currently a shortage of donor livers, so there is a need to find an alternative solution.
Over the past decade, major advancements have been made in regenerative Hepatology including breakthroughs in stem cell research and biotechnologies. Our aim is to implement and even replace liver transplantation and thereby serve a large patient group with an urgent medical need.
The EASL Consortium for Regenerative Hepatology is aimed at the delivery of bioengineered tissues and associated biotechnologies for regenerative Hepatology.
The Consortium is a multidisciplinary European-based organization including individual research groups or established centers willing to join efforts to achieve common goals and fosters the acquisition of financial resources to support the activity of the Consortium.